Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...

In addition to the updates for 2025, CVS offered its first look at expected earnings for 2026. The company said it ...

CVS Health used its Investor Day on Tuesday as a megaphone for the retailer’s success, raising its full-year financial ...

CVS Health (CVS) stock in focus as the company raises 2025 financial guidance, but projects 2026 revenue below consensus.

The company forecast 2026 adjusted profit ​to be in the range of $7.00 to $7.20 per share, compared with analysts' average ...

Exxon Mobil was one of the strongest forces lifting the market. It climbed 2.5% after increasing its forecast for profit over ...

CVS now expects revenue of at least $400 billion for 2025, up from its prior view of at least $397.3 billion. The company now expects adjusted earnings per share of $6.60 to $6.70, the midpoint of ...

CVS Health is projecting another year of solid earnings growth, announcing that its expected 2026 profit will surpass both Wall Street forecasts and its own 2025 earnings outlook. The update, shared ...

CVS Health on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signaling steady ...